Are the New FDA Warning Letters Signaling Treatment of Hemp Extracts as Over the Counter Monographs? March 23, 2021 Justin Walsh Hemp Policy & Legal 1 Comment The FDA issued two new warning letters on March 22, 2021. Previous rounds of warning letters have focused on whether the companies have made statements that would make the product a drug. These have focused on such things as (1)… Read More→
NIST and FDA May Be the Cannabis Quality Assurance Heroes We Need August 21, 2020 Hilary Bricken Compliance and Regulations, Policy & Legal 0 Comments By Hillary Bricken, Co-Founder Harris Bricken Over the years, we’ve pointed out when federal agencies opt to ignore the federal illegality of cannabis. It happens more often than you might think depending on the topic (see, for example, the NLRB).… Read More→